Brain Cancer Clinical Trials

Showing 1141-1160 of 1,466 trials

A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas

NCT01765088

This study is being conducted to help determine whether the addition of Interferon-alpha(α-IFN),which were determined sensitized the activity of Temozolomide(TMZ) in vivo and vitro, when given along with temozolomide during the monthly cycles that follow radiation, is able to delay tumor growth, shrink tumors, or impact how long people with newly diagnosed high-grade glioma.

Anaplastic OligoastrocytomaAnaplastic AstrocytomaGlioblastoma

Sun Yat-sen University300 participantsStarted Sep 2012

Guangzhou, Guangdong, China

COMPLETEDPhase 2

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

NCT01632228

This randomized, double-blind, placebo-controlled, multicenter phase II study will evaluate the safety and efficacy of onartuzumab in combination with bevacizumab as compared to bevacizumab alone in participants with recurrent glioblastoma. Participants will be randomized 1:1 to receive either placebo plus bevacizumab every 3 weeks, or onartuzumab plus bevacizumab. Study treatment will continue until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.

Glioblastoma

Hoffmann-La Roche135 participantsStarted Jun 2012

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +59 more locations

A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

Related Searches

Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery

Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study

Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients

MRI-Guided LITT for Treatment Metastatic Brain Tumors

Multi-site Validation and Application of a Consensus DSC-MRI Protocol

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Expanded Access for Pembrolizumab (MK-3475)

A Study of Apatinib in Recurrent or Recurrent High-grade Glioma

Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Differentiating Recurrent Brain Tumor Versus Radiation Injury Using MRI

Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Multimodality Imaging Combined With Multiple Targets Pathological Examination for Detecting of Biological Borders of Gliomas: a Clinical Application Study

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients

Using Genomic Analysis to Guide Individual Treatment in Glioblastoma

Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors